Assembly Biosciences (FRA:V7B) Common Stock : €0.01 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences Common Stock?

Assembly Biosciences's quarterly common stock declined from Jun. 2024 (€0.01 Mil) to Sep. 2024 (€0.01 Mil) but then increased from Sep. 2024 (€0.01 Mil) to Dec. 2024 (€0.01 Mil).

Assembly Biosciences's annual common stock increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.01 Mil) and increased from Dec. 2023 (€0.01 Mil) to Dec. 2024 (€0.01 Mil).

Assembly Biosciences Common Stock Historical Data

The historical data trend for Assembly Biosciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Common Stock Chart

Assembly Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

0.03

0.04

0.01

Assembly Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Assembly Biosciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Assembly Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

ASMB:USA V7B:Germany

Address

Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080

Website

https://www.assemblybio.com

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Assembly Biosciences Headlines

No Headlines